Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio, Inc. Presents Data on Combination Therapy with INB03(TM) on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

GlobeNewswire June 16, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of INmune Bio, Inc. - INMB

Newsfile June 15, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of INmune Bio, Inc. - INMB

Newsfile May 28, 2022

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595(TM) in Alzheimer's Disease

GlobeNewswire May 23, 2022

INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th

GlobeNewswire May 18, 2022

INmune Bio, Inc. Presents Data Demonstrating XPro(TM) Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

GlobeNewswire May 10, 2022

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

GlobeNewswire May 5, 2022

INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

GlobeNewswire April 28, 2022

INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference

GlobeNewswire April 25, 2022

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's disease

GlobeNewswire April 13, 2022

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022

GlobeNewswire April 11, 2022

INmune Bio, Inc. Highlights INKmune(TM) Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit

GlobeNewswire April 4, 2022

INmune Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the "NK Cells in Solid Tumors" Workshop at Innate Killer Summit

GlobeNewswire March 30, 2022

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD(TM) 2022

GlobeNewswire March 25, 2022

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD(TM) 2022 - International Conference on Alzheimer's and Parkinson's Diseases

GlobeNewswire March 15, 2022

INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference

GlobeNewswire March 14, 2022

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update

GlobeNewswire March 3, 2022

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3

GlobeNewswire February 23, 2022

INmune Bio, Inc. to Present at the BIO CEO & Investor Conference

GlobeNewswire February 8, 2022

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

GlobeNewswire January 25, 2022